

Imbruvica® (ibrutinib) - Indication and strength removals

- On May 18, 2023, the <u>FDA approved</u> revisions to the <u>Imbruvica (ibrutinib)</u> label to voluntarily remove the following indications:
 - Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
 - Treatment of adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
- In addition to the indication removals, the FDA also approved the removal of the Imbruvica 560 mg tablet. This strength was specifically approved for MCL and MZL.
- The FDA previously granted approval for Imbruvica in MCL and MZL based on overall response rates in two Phase 2 clinical studies under the accelerated approval pathway.
- The FDA approved label revisions follow an <u>April 6 announcement</u> from Janssen and AbbVie that
 they would be voluntarily withdrawing the MCL and MZL indications based on the results of the
 confirmatory Phase 3 trials.
- This decision does not affect any other approved indications for Imbruvica. Refer to the Imbruvica drug label for a complete list of Imbruvica's other approved uses.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.